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Abstract: Circulating tumour cells (CTCs) are an emerging resource for monitoring cancer biomarkers.
New technologies for CTC isolation and biomarker detection are increasingly sensitive, however,
the ideal blood storage conditions to preserve CTC-specific mRNA biomarkers remains undetermined.
Here we tested the preservation of tumour cells and CTC-mRNA over time in common anticoagulant
ethylene-diamine-tetra-acetic acid (EDTA) and acid citrate dextrose solution B (Citrate) blood tubes
compared to preservative-containing blood tubes. Blood samples spiked with prostate cancer cells
were processed after 0, 24, 30, and 48 h storage at room temperature. The tumour cell isolation
efficiency and the mRNA levels of the prostate cancer biomarkers androgen receptor variant 7 (AR-V7)
and total AR, as well as epithelial cell adhesion molecule (EpCAM) were measured. Spiked cells were
recovered across all storage tube types and times. Surprisingly, tumour mRNA biomarkers were
readily detectable after 48 h storage in EDTA and Citrate tubes, but not in preservative-containing
tubes. Notably, AR-V7 expression was detected in prostate cancer patient blood samples after 48 h
storage in EDTA tubes at room temperature. This important finding presents opportunities for
measuring AR-V7 expression from clinical trial patient samples processed within 48 h—a much more
feasible timeframe compared to previous recommendations.
Keywords: circulating tumour cell; biomarker; androgen receptor; AR-V7; droplet digital polymerase
chain reaction (ddPCR); blood storage tube
1. Introduction
Circulating tumour cells (CTCs) are cells shed from tumours into the peripheral blood, and are
believed to be the mechanism for metastasis [1,2]. The enumeration of CTCs has great prognostic
value, and further molecular profiling of CTCs has great potential in providing insights on cancer
progression, identifying CTC specific molecular therapeutic targets, determining prognostic and
relapse indicators, and allowing longitudinal monitoring of disease response to treatments [3,4].
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Therefore, relatively simple, non-invasive CTC analysis has exciting potential to investigate changes
in tumour biomarkers during a cancer patient’s disease progression. In prostate cancer, CTC counts
have been associated with prognosis and importantly, isolated CTCs can function as a surrogate
tumour samples to detect therapy-determining biomarkers, including the mRNA based androgen
receptor variant AR-V7 in CTCs [5–8]. However, CTC analysis is still a rapidly-evolving field due
to the complexities of isolation and detection of true CTCs. While it is estimated that 106 CTCs are
shed per 1 g of tumour tissue per day, CTCs are thought to have a short half-life of less than 3 h in the
bloodstream [9–12]. Hence, a major technical challenge for CTC analysis has been efficient recovery
of rare CTCs from a background of approximately 109 erythrocytes and 107 leukocytes per mL of
blood, and this has spurred the development of improved technologies for CTC isolation [13–15].
Despite these advances, feasible CTC analysis for clinical trials involving multiple sites are particularly
challenging, due to strict requirements for pre-analytical conditions of blood samples in transport
and storage, and time restrictions to ensure CTC integrity and biomarker detectability is maintained.
Parameters, such as blood tube composition, storage or shipping temperature, sample agitation,
and delays in sample processing in a large-throughput laboratory need to be considered before such
measurements are conducted for clinical trials. Ideally, CTCs should be protected from apoptosis or
cell lysis and, importantly, preserve relevant tumour biomarkers, an issue that is considered especially
challenging for mRNA-based biomarkers.
Ethylene-diamine-tetra-acetic acid (EDTA) and acid citrate dextrose solution B (Citrate) are
commonly used as anticoagulants in blood tubes for pathology blood tests. These tubes are compatible
with downstream polymerase chain reaction (PCR) analysis [16,17] and have also been used for
CTC isolation. However, as these tubes do not contain fixatives, early studies recommended that
blood should be processed within 24 h, and ideally within 5 h, as it was thought that CTCs
rapidly enter apoptosis [18]. To target this problem, new blood tubes have been designed with
preservatives intended to extend time before sample processing. Cell-free DNA blood collection tubes
(DNA BCT) and Cell-free RNA blood collection tubes (RNA BCT) (Streck, Omaha, NE, USA) are
proposed to stabilise nucleated blood cells, preventing the release of cellular DNA and RNA into the
plasma, and also inhibiting degradation of cell-free DNA and RNA [19,20]. Therefore, these tubes
might be advantageous for CTC sample analysis. Additionally, Cyto-Chex blood collection tubes
(Cyto-Chex BCT) were originally designed to preserve cell surface antigens for white blood cell
immunophenotyping [21] which may allow improved CTC recovery by immunomagnetic isolation.
There have been previous reports suggesting the added preservatives in BCTs indeed aids CTC
stability [22,23]. However, the preservative effects on actionable mRNA-based tumour biomarkers,
such as AR-V7 has, to our knowledge, not been tested thoroughly in CTCs isolated from any
blood collection tube type. We have previously reported a very sensitive method to detect AR-V7,
an emerging RNA-based prostate cancer biomarker in prostate cancer patient CTC samples, showing
that AR-V7 is not expressed in residual blood cells, and is expressed heterogeneously in CTCs [7].
In this study, we compare the effects of preservative-containing BCTs to commonly used EDTA and
Citrate blood tubes on tumour cell isolation and detection of AR-V7 using our sensitive method.
2. Results
2.1. Spiked Cell Recovery
To test CTC preservation and recovery from the five different blood tubes, CTCs were modelled
by spiking defined cell numbers of the 22Rv1 prostate cancer cell line into healthy female donor blood.
At 0, 24, 30, and 48 h after spiking, tumour cells were enriched and enumerated. Three experiments
were performed using 192 mL blood each from three healthy donors. The mean recovery of spiked
cells ranged from 13% to 44% across all time points. All blood tubes showed preservation of spiked
cells up to 48 h, with mean recovery between 24% and 39% (Figure 1a). The mean recovery of all blood
tubes at each time point was compared against recovery at 0 h. Processing samples at 24 and 30 h
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resulted in significantly lower recovery than when processed at 0 h (p < 0.05). Within each time point,
the recovery of each blood tube was compared to EDTA. No blood tube had significantly different
recovery from EDTA, but the mean recovery of RNA BCT exceeded EDTA at each time point (p < 0.05).
Figure 1. (a) Recovery of spiked 22Rv1 cells after tumour cell enrichment. The mean recovery at 24 h
and 30 h was significantly different from recovery at 0 h (* p < 0.05). (b) Total cell count (recovered
spiked cells and residual leukocytes after cell enrichment) from samples processed 0 h, 24 h, 30 h,
and 48 h after spiking. At 48 h, DNA blood collection tubes (DNA BCT) cell count was significantly
different from ethylene-diamine-tetra-acetic acid (EDTA) (* p < 0.05). For both (a,b), symbols represent
the mean from three independent experiments, and whiskers represent the range.
2.2. Leukocyte Contamination
DNA BCT and RNA BCT generally had increased total cell counts (tumour cells plus residual
co-purified leucocytes) when samples were processed later (Figure 1b). In comparison, EDTA, Citrate
and Cyto-Chex BCT cell counts remained similar across all time points. When compared to EDTA
tubes, DNA BCT and RNA BCT had higher mean cell counts at each time point, whereas Citrate tubes
gave lower cell counts. A two-way ANOVA of each blood tube compared to EDTA at the same time
point indicated that for samples processed at 48 h, DNA BCT total cell counts were significantly higher
than for EDTA tubes (p < 0.05).
2.3. Cellular RNA Recovery
To evaluate the ability of each blood tube in preserving cellular RNA, tumour cell-specific gene
expression (AR-V7, total AR and epithelial cell adhesion molecule (EpCAM)) was measured by
droplet digital PCR (ddPCR) for each blood tube at each tumour cell enrichment time point (Figure 2).
Cells from EDTA and Citrate tubes generally showed decreased mRNA detection the longer the sample
storage time, with mRNA biomarkers still readily detectable even after 48 h. In all BCT samples,
gene expression was low when processed immediately and undetectable after any storage duration.
Thus, while mRNA detection from Citrate and EDTA blood tube samples was similar, BCT samples
showed a striking loss in detectable gene expression compared to EDTA tube samples (p < 0.01).
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Figure 2. Expression of spiked tumour cell specific genes in samples processed 0 h, 24 h, 30 h, and 48 h
after spiking. Symbols represent mean expression from three independent experiments, whiskers
represent the range, and are not shown when smaller than the data symbol. The mean gene expression
in DNA BCT, RNA BCT, and Cyto-Chex BCT were significantly different from EDTA (** p < 0.01,
*** p < 0.001, **** p < 0.0001). AR-V7: androgen receptor variant 7; AR: androgen receptor.
2.4. Increased Proteinase K Treatment
We also investigated the effect of increased proteinase K digestion on the cellular RNA recovery
as per manufacturer’s suggestions for the BCTs. 22Rv1 cells were spiked into a new set of blood tubes
(EDTA, Citrate, DNA BCT, and RNA BCT), followed by enrichment after 48 h of storage. RNA was
extracted with and without additional 2 h proteinase K treatment, and gene expression was measured
in RNA samples from two independent experiments. In EDTA and Citrate blood tubes, increased
proteinase K digestion did not aid RNA recovery but decreased the number of measured copies of
all three genes (Figure 3). In DNA BCT and RNA BCT, there was no detectable AR-V7, total AR or
EpCAM with standard RNA extraction, and with increased digestion there was a small, but statistically
insignificant, increase in the detection of total AR and AR-V7 in DNA BCT and RNA BCT, respectively.
Figure 3. Effect of increased proteinase K treatment on the detection of spiked cell specific genes in
samples processed 48 h after spiking. Symbols represent the mean expression from two independent
experiments, whiskers represent the range, and are not shown when smaller than the data symbol.
EpCAM: epithelial cell adhesion molecule.
2.5. Patient CTC Cellular RNA Detection
Given that spiked cell-specific gene expression was detectable even in samples processed 48 h
following spiking of 22Rv1 cells into fresh blood in EDTA and Citrate tubes, we wished to confirm
that AR-V7 also remains detectable that long in patient-derived CTCs. Common EDTA tube blood
samples from three prostate cancer patients were processed at 4, 24, and 48 h after collection. After CTC
enrichment, all patient samples had detectable AR-V7, total AR and EpCAM at all time points (Figure 4).
AR-V7 expression varied between the three patients, while being comparable to the expression detected
for these patients in a sample collected previously (Table 1). The AR-V7 and total AR detected in patient
samples decreased with longer time before processing, but the decrease was not statistically significant.
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Figure 4. Detection of gene expression in prostate cancer patient circulating tumour cells (CTCs)
isolated 4, 24, and 48 h after blood collection in EDTA tubes. Error bars represent 95% confidence
intervals of droplet digital polymerase chain reaction (ddPCR) measurements, and error bars smaller
than the data symbols are not shown.





CTC Count/mL Blood AR-V7 Copies/mL Blood Total AR Copies/mL Blood
<4 h * <4 h * 4 h 24 h 48 h <4 h * 4 h 24 h 48 h
1 CRPC 9 * 2 * 7 5 3 96 * 155 49 84
2 CRPC 2 * 110 * 126 128 74 19,140 * 7963 6083 4191
3 CRPC 6 * 45 * 210 135 102 2610 * 11,392 5994 3848
1 CRPC = castrate resistant prostate cancer. Patients who had 7–9 month previously high AR-V7 levels detected [7]
were chosen for this study (* for comparison previous data are presented; note in the previous study CTC isolation
was performed using a different instrument (IsoFlux, Fluxion, San Francisco, CA, USA), CTC counts are normalized
per mL blood). New AR-V7 and total AR expression data of the same patients are presented.
3. Discussion
3.1. Tumour Cell Preservation
New blood tubes such as DNA BCT, RNA BCT, and Cyto-Chex BCT contain formaldehyde-free
fixatives in addition to traditionally used anticoagulants in blood tubes [19–21]. As these BCTs were
previously shown to preserve leukocytes and prevent the release of cellular RNA into plasma, even after
over three days of storage at room temperature [20,24,25], our study compared commonly-used EDTA
and Citrate tubes with BCTs in terms of the ability to preserve modelled CTCs (spiked cultured tumour
cells) and of greater interest, cellular RNA.
From our study, the total cell count by Hoechst staining showed that leukocyte retention after
tumour cell enrichment increased over time in DNA BCT compared to other blood tubes. Since BCTs
were designed for analysis of plasma cell-free nucleic acids, this has not previously been a concern.
However, downstream analysis of CTCs can be adversely affected by contaminating leukocytes,
such as for single CTC isolation or CTC nucleic acid analysis. Disregarding background leukocytes,
intact tumour cells were visible under bright field microscopy from all blood tubes after 48 h (data not
shown), and enumeration of cell tracker-stained cells indicated that the recovery of spiked tumour
cells was not significantly different across all blood tube types within each time point. Furthermore,
although spiked cell recovery generally decreased with longer storage time before processing, there
was no significant difference between recovery at 0 and 48 h, with a mean recovery of 35% and 30%,
respectively. Our results are in agreement with a previous study which found that CTC yields from
lung cancer patients did not decline significantly when processed after 24, 48, or 72 h storage in EDTA
tubes [26]. We suggest that the observed variation in spiked cell recovery in our data can be mostly
attributed to the difficulties of spiking exact cell numbers of the 22Rv1 cell line, which shows a very
strong tendency towards cell clustering. Nevertheless, this line was chosen due to its high AR-V7
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expression, and cell strainers were used to keep the effects of cell aggregates to a minimum. Conversely,
our results differ from a recent study which reported that the recovery of 2000 spiked MCF-7 breast
cancer cells from DNA BCT after one day and four days was very similar at 60% and 58%, respectively,
while the recovery decreased from 32% to 16% for EDTA tubes [23]. The discrepancies between the
results may be attributed to the difference in the spiked cell line, spiked cell numbers, method of
tumour cell isolation, and detection and blood storage time. Importantly, the observed differences in
the limited number of studies in this area highlights the need for more research to further compare
and improve methods of CTC isolation after blood storage.
Despite common recommendations to process blood samples as soon as possible to reduce cell
lysis, our data indicates that cell fixation is not necessary for the recovery of tumour cells, and common
EDTA or Citrate tubes are sufficient for tumour cell detection within 48 h.
3.2. Cellular RNA Preservation
Analysis of gene expression from CTCs can provide valuable information on CTC activity and
cancer progression, but is particularly challenging as delays in blood sample processing may cause
alterations in CTC gene expression, and existing mRNAs may have a short half-life. DNA BCT and
RNA BCT were designed to preserve cellular DNA and RNA, respectively, from being released and,
hence, were expected to perform better than commonly-used EDTA and Citrate tubes, which only
contain anticoagulants. We used our previously-reported, highly-sensitive and specific ddPCR assay
to screen for AR-V7, total AR, and EpCAM; this assay has shown before that AR-V7 and total AR were
highly expressed in the 22Rv1 cell line or patient CTCs while having no, or negligible, expression in
healthy control peripheral lymphocytes [7]. We were surprised to find AR-V7, total AR, and EpCAM
readily detectable after 48 h in common EDTA and Citrate tubes. The data suggest that mRNAs
encoding these genes have relatively long half-life and/or are continuously expressed by viable
tumour cells during storage in a blood sample. Additionally, the detection of mRNA confirms that
cells remain intact in the blood sample as it is well established that any released free RNA will be
quickly degraded by RNases in the blood [27]. Since cultured 22Rv1 cells are potentially more robust
and survive extended storage in blood samples better than CTCs, we confirmed that AR-V7 detection
after 48 h storage was translatable to patient CTC samples by testing three patients previously shown
to have high CTC AR-V7 expression [7]. Although a small decrease in AR-V7 levels after 48 h was
detected in these patient samples, the decrease was marginal in this time frame and even in patient
blood with low AR-V7, CTC derived AR-V7 was still detectable after 48 h blood storage at room
temperature. AR-V7 expression was comparable to the previous testing of the same patients [7].
In contrast to our data from blood storage in common blood tubes, the BCT samples processed
immediately produced much lower detectable tumour cell specific mRNA, and any storage of spiked
blood samples in these tubes prevented detection of gene expression completely. We propose that the
preservative in the tubes renders RNA inaccessible, likely due to RNA cross-linking with proteins and
DNA, which would be incomplete when samples are processed immediately, explaining the limited
gene expression detected for our 0 h samples. This interpretation is supported by a report that spiked
breast cancer cells could be retrieved from DNA BCTs after up to 72 h storage and had accessible DNA,
however, whole genome amplification (WGA) yielded consistently significantly less DNA than WGA
from EDTA tubes [22]. Alternatively, RNA could have degraded in the BCTs in our study, however,
mRNA was reported detectable by in situ hybridisation from spiked tumour cells isolated from blood
stored for four days at room temperature in DNA BCTs [23], suggesting that RNA remains intact
but possibly cross-linked, which would interfere less with in situ hybridisation than RNA extraction.
While, according to the manufacturers guidelines, RNA should be extractable from samples stored in
BCTs, an extended protein K digest is recommended, which might help to reverse cross-linking effects.
We, therefore, investigated whether increased proteinase K treatment during RNA extraction would
allow relevant gene expression detection for samples stored for 48 h. However, increased proteinase K
digest failed to produce relevant effects and decreased RNA detectability in EDTA and Citrate tubes.
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Previous studies showed BCTs to preserve leukocyte cellular RNA, and prevent cellular RNA
contamination of cell-free RNA [20,24]. Additionally, the detection of cellular GAPDH, c-Fos and
p53 RNA was reported to show variation in expression in neutrophils from blood samples stored over
three days in EDTA tubes, whereas there was no change when stored in RNA BCT [25]. While the
reasons for the difference to our data are not completely clear, it stands out that all genes tested in
that study are abundantly-expressed genes in common blood cells, which might be easier to detect.
We have not extended testing past 48 h, as blood samples from within Australia can be processed in
this time frame in our facility; however, it is an area of interest for future studies to determine the
maximum storage time for EDTA and Citrate tubes.
From our data, it is evident that CTC-derived AR-V7 can be detected from blood stored in
commonly-used EDTA and Citrate tubes for up to 48 h, while blood tubes with preservatives
(DNA BCT, RNA BCT, and Cyto-Chex BCT) should not be used for CTC isolation if downstream RNA
analysis by PCR is intended.
4. Materials and Methods
4.1. Blood Collection
Prostate cancer patients (n = 3) and healthy female blood donors (n = 4) provided written informed
consent to participate in the study. The study was approved by the South Western Sydney Local
Healthy District Ethics Committee, Australia (HREC/13/LPOOL/158; 02/09/2013). Peripheral blood
was drawn by venipuncture into blood tubes with the initial 3 mL discarded to prevent keratinocyte
contamination and false positive CTCs being present. For the main comparison experiment, a total
of 192 mL blood from each healthy donor (n = 3) was drawn into a total of 24 blood tubes including:
4 × 9 mL K3EDTA tube (Greiner Bio-One, Kremsmünster, Austria), 4 × 9 mL acid citrate dextrose-B
tube (Greiner Bio-One, Kremsmünster, Austria), 4 × 10 mL Cell-free DNA BCT (Streck, Omaha, NE,
USA), 4 × 10 mL Cell-free RNA BCT (Streck, Omaha, NE, USA), and 4 × 2 × 5 mL Cyto-Chex BCT
(Streck, Omaha, NE, USA). In the follow-up experiment to test increased proteinase K treatment, 38 mL
blood from two healthy donors was drawn into one set of EDTA, Citrate, and DNA BCT and RNA
BCT tubes. In the experiment with prostate cancer patients, blood was drawn into 3 × 6 mL K2EDTA
tubes (BD, Franklin Lakes, NJ, USA) available in the clinic.
4.2. Cell Spiking
The human prostate cancer cell line 22Rv1 was purchased from the American Type Culture
Collection (In Vitro Technologies, Melbourne, Australia). Cells were routinely passaged in Roswell
Park Memorial Institute culture medium (RPMI 1640) (Lonza, Basel, Switzerland) supplemented
with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA) in a humidified incubator
with 5% CO2 at 37 ◦C. For spiking experiments, 22Rv1 cells, cultured for two days after passaging,
were gently detached with accutase (Sigma-Aldrich, St. Louis, MO, USA), washed with phosphate
buffered saline (PBS), and passed through a 20 µm pre-separation filter “cell strainer” (Miltenyi Biotec,
Bergisch Gladbach, Germany) to remove cell aggregates. Cells were then incubated with 15 µM
CellTracker Green CMFDA (Life Technologies, Carlsbad, CA, USA) in 100 µL serum-free RPMI media
at 37 ◦C for 1 h. Stained 22Rv1 cells were washed with PBS and a known number (100–200 cells)
were spiked into blood tubes. The spiked input cell numbers were verified by aliquoting the same
volume onto glass slides in between inoculating blood samples, Hoechst staining, and enumeration by
fluorescent microscopy.
4.3. Tumour Cell Enrichment from Whole Blood
Spiked blood samples were enriched for tumour cells after storage (dark, room temperature)
for 0, 24, 30, and 48 h. The peripheral blood mononuclear cell (PBMC) layer was extracted using
50 mL SepMate tubes and Lymphoprep according to the manufacturer’s instructions (Stemcell
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Technologies, Vancouver, BC, Canada). PBMCs were washed with separation buffer (PBS with
0.5% FBS and 2 mM EDTA), then incubated at 4 ◦C for 30 min with 50 µL FcR blocking reagent
(Miltenyi Biotec, Bergisch Gladbach, Germany), 50 µL EpCAM conjugated immunomagnetic
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), 1 µL 50× Hoechst (Fluxion, San Francisco,
CA, USA), and made up to a total volume of 500 µL with separation buffer. Cell separation
was performed with the Posselds program on the AutoMACS Pro Separator (Miltenyi Biotec,
Bergisch Gladbach, Germany). After separation, the positive selected fraction was separated into two
aliquots: one was kept on ice until enumeration on the same day, while the other was centrifuged
at 400× g for 10 min, and the pellet frozen at −80 ◦C until RNA extraction. For testing of extended
proteinase K treatment, samples were enriched after 48 h, with both aliquots frozen at −80 ◦C until
RNA extraction. For prostate cancer patient samples, one blood tube from each patient was processed
within 4 h of blood draw, and the other two blood tubes were processed after 24 and 48 h of storage,
respectively, before freezing at −80 ◦C until RNA extraction. Supplementary Figure S1 illustrates the
different work flows.
4.4. Cell Enumeration
The enriched enumeration sample was mounted onto slides coated with 2% bovine serum
albumine (BSA), then visualised and scanned at 20× magnification with a CellCelector microscope
(ALS GmbH, Jena, Thüringen, Germany). The exposure times for the instrument’s DAPI and FITC
channels were 50 ms and 100 ms, respectively. Scanned images were analysed with ALS CellCelector
software v3.0 (ALS GmbH). Nucleated (Hoechst-positive) cells were detected for total cell counts,
while cells positive for both Hoechst and CellTracker were considered recovered spiked cells.
To calculate the percentage recovery of spiked cells, the number of cells enumerated after tumour
cell enrichment was multiplied by two (to account for CTCs being enumerated in half of the sample
while the other half was processed for RNA) and then divided by the original number of spiked cells
as determined from input controls.
4.5. Cellular RNA Extraction
Total RNA was extracted from the second enriched sample or from CTC-enriched patient samples
with the Total RNA Purification Micro Kit (Norgen Biotek Corp., Thorold, ON, Canada). RNA was
double-eluted in 20 µL followed by 10 µL molecular-grade H2O. For complementary DNA (cDNA)
synthesis, 15 µL of eluted RNA was added to form a total volume of 20 µL with the SensiFAST cDNA
Synthesis Kit (Bioline, London, UK). For testing increased proteinase K digestion, 0.5 mg of DNAase
and RNAase free proteinase K (Bioline) was added with buffer RL at the cell lysate preparation step,
and the sample was incubated for 2 h at 60 ◦C before the addition of ethanol.
4.6. Digital Droplet PCR
Quantification by ddPCR was performed for three tumour cell specific genes. Total androgen
receptor (total AR), androgen receptor splice variant 7 (AR-V7), and epithelial cell adhesion molecule
(EpCAM) using primers and probes shown in Table 2. In brief, 20 µL ddPCR reactions contained 10 µL
ddPCR Supermix for Probes (No dUTP) (Bio-Rad, Hercules, CA, USA), 500 nM of each relevant primer
and 250 nM probe Fluorescein (6-FAM) or HEX. Total AR and AR-V7 reactions were multiplexed as
previously-described [7]. Droplets were generated with 70 µL oil using a QX200 droplet generator
(Bio-Rad). Amplification was performed at 95 ◦C for 10 min, followed by 40 cycles of 94 ◦C for 30 s
and 55 ◦C for 1 min using a C1000 Touch Thermo Cycler (Bio-Rad). After amplification, the droplets
were read with a QX200 Droplet Reader (Bio-Rad) and analysed with QuantaSoft software v1.7.4.
The fluorescence thresholds used were 6-FAM 2000 for AR-V7, HEX 2500 for total AR, and HEX 1500
for EpCAM. Readings with ≥5 droplets were considered positive. The total error calculated by the
software was used as the 95% confidence intervals of ddPCR measurements.
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Table 2. Primers and probes.
Gene Primers (5′→3′) Probes (5′→3′)
Total AR F: GGA ATT CCT GTG CAT GAA AGCR: CGA TCG AGT TCC TTG ATG TAG TTC [HEX] CTT CAG CAT TAT TCC AGT G [BHQ1]
AR-V7 F: CGG AAA TGT TAT GAA GCA GGG ATG AR: CTG GTC ATT TTG AGA TGC TTG CAA T [6FAM] TCT GGG AGA AAA ATT CCG [BHQ1]
EpCAM F: CGT CAA TGC CAG TGT ACT TCAR: TTT CTG CCT TCA TCA CCA AA [HEX] TAC TGT CAT TTG CTC AAA GC [BHQ1]
AR: androgen receptor; AR-V7: androgen receptor variant 7; EpCAM: epithelial cell adhesion molecule;
6FAM: Fluorescein; BHQ1:black hole quencher 1. F: Forward, R: Reverse.
4.7. Statistical Analysis
Analysis of cell and RNA recovery was performed by two-way Analysis of Variance (ANOVA),
using GraphPad Prism software v6.07 (GraphPad Software Inc., San Diego, CA, USA).
5. Conclusions
While spiked cell recovery was not affected by the blood tube type even after 48 h of storage,
tumour cell-specific RNA was undetectable by ddPCR in CTCs from stored blood samples containing
preservatives, likely due to crosslinking effects suppressing RNA accessibility. Surprisingly, AR-V7
was readily detectable in patient CTCs enriched from common EDTA blood tubes after up to 48 h.
Although BCTs have been thoroughly tested for circulating tumour nucleic acid detection [28–33],
and some initial studies of blood storage in BCTs for tumour cell analysis were also encouraging
when using image-based cell analysis involving fluorescent probing for proteins or nucleic acids [23],
our data suggests that RNA extraction and downstream analysis by PCR-based methods is severely
impeded by the preservatives.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/5/1047/s1.
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